Transcaval Access for Transcatheter Aortic Valve Replacement in People With No Good Options for Aortic Access

PHASE1CompletedINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

October 30, 2014

Primary Completion Date

July 27, 2017

Study Completion Date

December 28, 2018

Conditions
Aortic Valve Stenosis
Interventions
PROCEDURE

CA-TAVR

Transcaval acesss for transcatheter aortic valve replacement in patients with no good options for aortic access

DEVICE

Amplatzer Duct Occluder

Trial Locations (15)

17403

York Hospital, York

20010

Medstar Washington Hospital Center, Washington D.C.

22042

INOVA Fairfax Hospital, Falls Church

22908

University of Virginia Medical Center, Charlottesville

23507

Sentara Norfolk General Hospital, Norfolk

24014

Carilion Medical Center, Roanoke

27103

Wake Forest University, Winston-Salem

37232

Vanderbilt Heart and Vascular Institute, Nashville

48202

Henry Ford Hospital, Detroit

60181

Advocate Heart Institute, Oakbrook Terrace

60201

NorthShore University HealthSystem, Evanston Hospital, Evanston

70121

Ochsner Health System, New Orleans

70360

Cardiovascular Institute of the South, Houma

74104

Oklahoma Heart Institute, Tulsa

30322-1102

Emory University, Atlanta

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT02280824 - Transcaval Access for Transcatheter Aortic Valve Replacement in People With No Good Options for Aortic Access | Biotech Hunter | Biotech Hunter